T cell-based immunotherapies, including immune checkpoint blockade and chimeric antigen receptor (CAR) T cells, have transformed outcomes in several cancers. Yet their effectiveness is routinely undermined by two barriers built by the tumor itself. The first is intrinsic resistance: tumor cells downregulate antigen presentation and display checkpoint molecules such as PD-L1 and CD73 that shut down approaching T cells. The second is the tumor microenvironment itself, which becomes dominated by M2-like tumor-associated macrophages, cells that secrete immunosuppressive cytokines, impair antigen presentation, and actively suppress anti-tumor responses. Most therapeutic strategies address one barrier at a time; the new work demonstrates that a single microRNA can act on both.

The researchers focused on microRNAs, short non-coding RNA molecules of roughly 22 nucleotides that bind complementary sequences in messenger RNAs and dampen protein production. Because each microRNA can regulate dozens of targets at once, they are uniquely positioned to orchestrate broad, coordinated changes in cell behavior, a property the team set out to exploit deliberately. Their central question was whether miR-155-5p, and a related candidate called miR-3535, could drive functional reprogramming of both tumor cells and macrophages in a concerted fashion.

Experimentally, the approach was straightforward but comprehensive. Human tumor cell lines drawn from several different cancer entities were transfected with synthetic miR-155-5p or miR-3535, and the resulting changes in immune checkpoint molecule expression and cell proliferation were measured at both the transcript and protein level. In parallel, M2-polarized macrophages generated from peripheral blood mononuclear cells of healthy donors received the same microRNA treatment. The team then profiled cytokine secretion by enzyme-linked immunosorbent assay and carried out transcriptomic analysis, combining RNA sequencing with microarray-based gene expression profiling, to map the macrophage polarization states and immune-regulatory pathways altered by treatment. Transcription factor activity and gene set enrichment analyses were used to identify the regulatory circuits at work.

The results in tumor cells were striking. Both microRNAs reduced expression of CD73, encoded by the NT5E gene, an ectoenzyme that degrades extracellular ATP into immunosuppressive adenosine and is widely regarded as a driver of tumor immune escape. miR-155-5p went further, also suppressing PD-L1 (CD274), the ligand targeted by some of the most widely used checkpoint inhibitor drugs. Knocking down both molecules in a single step effectively removes two of the brakes tumors place on T cells, one that blocks T cell activation through the PD-1 axis and one that poisons the metabolic environment around the tumor.

The macrophage findings were equally significant. When M2-like macrophages, the immunosuppressive, wound-healing subtype that accumulates in tumors, were transfected with either microRNA, they shifted toward a pro-inflammatory M1-like phenotype. This conversion was measurable functionally: treated macrophages secreted markedly more TNFα, a cytokine with direct anti-tumor activity, and CXCL10, a chemokine that recruits activated T cells into tissues. Gene expression analysis confirmed the induction of M1-associated genes across the board.

The transcriptomic data revealed the mechanism in finer detail. MicroRNA treatment activated inflammatory signaling pathways driven by STAT1, a signal transducer and activator of transcription, and by interferon regulatory factors, the downstream effectors of interferon signaling that define the classical inflammatory macrophage state. At the same time, the activity of ZNF703, a zinc finger transcription factor that the study identifies as a transcriptional hub associated with M2 macrophage infiltration and poor clinical prognosis, was reduced. In other words, the microRNAs did not merely nudge macrophages; they flipped the regulatory logic of the cell, amplifying the inflammatory program while simultaneously quieting a master regulator of the tumor-permissive state.

A further observation points to a possible bonus effect on the anti-tumor immune response itself. Both microRNAs increased expression of TAP1, the transporter associated with antigen processing 1, a critical component of the machinery that loads peptide fragments onto MHC class I molecules for display to cytotoxic T cells. Enhanced TAP1 expression suggests improved antigen-processing capacity, potentially making tumor cells and antigen-presenting cells more visible to the immune system. This is particularly relevant because loss of antigen presentation is a well-documented route by which tumors escape both natural immune surveillance and T cell-based therapies.

Beyond their immunological effects, both microRNAs exerted direct anti-proliferative effects across tumor cell lines from multiple entities. That the same molecule slows tumor growth while simultaneously reversing checkpoint expression and repolarizing macrophages is what distinguishes this work from more narrowly targeted approaches. The findings link tumor cell plasticity to neutralization of the immunosuppressive tumor environment within a single regulatory mechanism, rather than treating these as separate problems requiring separate drugs.

The broader implications for cancer immunotherapy are considerable. Current strategies to overcome immune resistance typically involve combining checkpoint inhibitors with each other or with chemotherapy, radiation, or macrophage-targeting agents, an approach that multiplies toxicity and cost. A microRNA-based strategy that acts on several fronts at once could, in principle, simplify this combinatorial challenge. The authors note that the findings support further investigation of microRNA-based strategies in cancer immunotherapy, and the field has already developed delivery tools, including lipid nanoparticles, that could in theory carry synthetic microRNAs to tumors and tumor-associated immune cells in vivo.

Caution is warranted, as always in preclinical work. The experiments were conducted in cell lines and in donor-derived macrophages, not in patients, and the challenge of delivering a microRNA selectively to the right cells in a living tumor remains formidable. miR-155 in particular is a pleiotropic molecule with roles in inflammation and immunity that cut both ways; systemic elevation could carry inflammatory risks, and past clinical experience with nucleic acid therapeutics has taught the field to be skeptical of simple delivery assumptions. The question of dose, timing, and tissue specificity will need to be answered in animal models and, eventually, carefully designed clinical studies.

Even so, the conceptual contribution is substantial. The study demonstrates that microRNAs are capable of coordinating anti-tumor effects across different cell types, a property that individual protein-targeting drugs rarely possess. If the coordinated reprogramming seen in vitro can be reproduced in vivo, miR-155-5p and miR-3535 would represent a template for a new class of immunotherapy, one that does not simply block a single checkpoint or deplete a single cell population, but rewires the conversation between tumor and immune system at multiple points simultaneously. At a time when the majority of patients still do not benefit from existing immunotherapies, strategies that address tumor-intrinsic resistance and microenvironmental suppression in one stroke are exactly the kind of innovation the field has been searching for.

T cell receptor-engineered T cells have been heralded as a frontier in targeted cancer therapy, enabling personalized attacks on tumor cells by tailoring the TCR specificity to cancer-associated antigens. However, a persistent limitation has been the suboptimal activity of T cells with low avidity TCRs, which fail to sustain a strong enough signal to effectively eradicate malignant cells. This low avidity often results from the delicate balance needed to avoid off-target toxicity and autoimmunity, constraining the clinical impact of these therapies. The discovery that TIGIT disruption can amplify the otherwise weak TCR signal provides a compelling solution to this stalemate.

TIGIT, or T cell immunoreceptor with Ig and ITIM domains, functions as an immune checkpoint receptor predominantly expressed on T cells and natural killer (NK) cells. It plays a crucial regulatory role by inhibiting immune responses and maintaining self-tolerance. However, in the tumor microenvironment, TIGIT’s inhibitory signaling dampens the antitumor activity of T cells, contributing to immune escape mechanisms leveraged by cancer cells. By genetically disrupting TIGIT in engineered T cells, the researchers effectively removed this inhibitory brake, allowing for a robust amplification of TCR signaling pathways.

Mechanistically, the team demonstrated that TIGIT disruption led to increased phosphorylation cascades downstream of the TCR complex, including key signaling nodes such as ZAP-70, LAT, and ERK. This enhanced intracellular signaling translated into improved functional responses, as TIGIT-deficient T cells exhibited heightened proliferation, cytokine production, and cytotoxicity against tumor cells expressing the target antigen. The increase in signaling strength overcame the intrinsic low avidity of the engineered TCRs, effectively converting them into more potent antitumor effectors without increasing autoreactivity.

Additionally, the study delved deeply into the phenotypic and transcriptional profiles of these TIGIT-deficient T cells. Using single-cell RNA sequencing and flow cytometry analyses, the authors revealed that these cells adopted a more activated and less exhausted state, featuring upregulation of effector molecules such as granzyme B and interferon-gamma. Notably, the modified T cells maintained a memory-like phenotype that favors persistence and long-term tumor surveillance. This phenotype is critical in the context of solid tumors, where continuous antigen exposure often leads to T cell exhaustion and therapeutic failure.

The researchers also explored the impact of TIGIT disruption within the complex tumor microenvironment. Using murine models of solid cancers, they showed that TIGIT-deficient TCR-engineered T cells not only infiltrated tumors more efficiently but also altered the immunosuppressive milieu. Tumors treated with these T cells exhibited lower levels of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), indicating a reshaping of the microenvironment conducive to sustained immune attack. These findings underscore the dual benefit of TIGIT disruption—intrinsic enhancement of TCR signaling and broader modulation of tumor immunity.

Critically, the safety profile of TIGIT disruption was meticulously evaluated. Unlike some checkpoint blockade strategies that unleash widespread immune activation and risk severe autoimmune side effects, the targeted genetic ablation of TIGIT in TCR-engineered T cells appears to retain antigen specificity without promoting off-target toxicity. This selectivity is crucial for clinical translation, as it minimizes the potential for adverse events while maximizing therapeutic benefit.

The study’s authors advocate that this approach could be seamlessly integrated into existing TCR-engineered T cell platforms, offering a scalable path for improved immunotherapy products. Furthermore, they suggest that TIGIT disruption could synergize with other immunomodulatory agents, such as PD-1 blockade or cytokine therapies, to further enhance antitumor responses. Such combination strategies could expand the therapeutic window and efficacy for patients with refractory solid tumors and hematologic malignancies.

From a broader perspective, this research addresses a fundamental challenge in adoptive T cell therapy: balancing T cell receptor affinity and avidity to achieve potent antitumor activity without off-target damage. By focusing on intracellular signaling modulation rather than merely improving TCR binding affinity, the TIGIT disruption strategy provides a novel axis for intervening in T cell functionality. This mechanistic insight could inspire the development of additional checkpoint-modulating approaches to optimize TCR signaling and immune persistence.

The translational potential of this work is underscored by ongoing developments in gene-editing technologies, such as CRISPR/Cas9, which enable precise and efficient TIGIT knockout in therapeutic T cells. Coupled with advances in manufacturing and adoptive transfer protocols, the integration of TIGIT disruption into next-generation T cell products could soon enter clinical testing. This would mark a significant leap forward toward personalized cancer therapies that are both safer and more effective.

Looking ahead, the research community is poised to explore how TIGIT disruption affects the behavior of TCR-engineered T cells in diverse tumor types, including those with notoriously suppressive microenvironments like pancreatic and glioblastoma cancers. Moreover, understanding the long-term consequences of TIGIT loss on T cell metabolism, exhaustion resistance, and memory formation will be critical to fully harnessing this approach. Such investigations will help optimize dosing strategies and identify biomarkers predictive of therapeutic response.

The findings reported by Spiga, Potenza, Magnani et al. represent a pivotal milestone in the field of immune checkpoint biology and adoptive cell therapy. By illuminating the molecular mechanisms through which TIGIT restrains TCR signaling, and demonstrating how its disruption revitalizes low avidity T cells, the researchers have opened new therapeutic avenues. Their work exemplifies the power of combining genetic engineering with immunological insights to overcome longstanding barriers in cancer treatment.

Ultimately, this breakthrough offers renewed hope for patients battling cancers resistant to current immunotherapies. It underscores the dynamic interplay between receptor signaling strength and immune regulation and the potential to tip this balance in favor of durable anticancer immunity. As the oncology field continues to evolve, the refinement of engineered T cell therapies through checkpoint targeting like TIGIT disruption could dramatically reshape clinical outcomes and broaden the reach of life-saving immunotherapies.

Subject of Research:
The study focuses on the disruption of the immune checkpoint receptor TIGIT to enhance the antitumor efficacy of low avidity T cell receptor-engineered T cells by increasing TCR signal strength.

Article Title:
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Article References:
Spiga, M., Potenza, A., Magnani, Z. et al. TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength. Nat Commun (2026). https://doi.org/10.1038/s41467-025-67263-w

Image Credits:
AI Generated

Chemotherapy remains a cornerstone of cancer treatment, yet its efficacy is frequently undermined by tumours’ ability to resist and evade therapeutic attack. Central to this resistance is the presence of tumour-associated macrophages (TAMs), a subset of immune cells that infiltrate tumour microenvironments, particularly clustering around tumour vasculature. These macrophages serve as immunological gatekeepers, creating a fortress-like barrier that prevents beneficial immune cells from penetrating tumours and supporting chemotherapy’s effectiveness.

The team from King’s College London has identified a critical protein produced by these macrophages—heme oxygenase-1 (HO-1)—which plays a pivotal role in this immune evasion strategy. HO-1 catalyzes the degradation of heme into biliverdin, iron ions, and carbon monoxide, exerting potent anti-inflammatory and cytoprotective effects within the tumour milieu. By leveraging this enzymatic function, the macrophages effectively shield cancer cells from immune-mediated destruction as well as the cytotoxic effects of chemotherapeutic agents.

To disrupt this protective shield, researchers engineered a small molecule inhibitor named KCL-HO-1i, designed specifically to inhibit HO-1 activity. The targeted inhibition of HO-1 undermines the macrophages’ ability to protect tumour cells, thereby restoring immune surveillance and enhancing chemotherapy efficacy. This strategic targeting represents an innovative angle in tumour immunotherapy, focusing on the tumour microenvironment rather than directly attacking cancer cells.

Professor James Arnold, leading the Tumour Immunology Group at King’s College London, emphasizes the significance of this approach: “Our discovery reveals that HO-1 expression in tumour-associated macrophages is a key factor limiting chemotherapy effectiveness. KCL-HO-1i enables us to modify the tumour microenvironment, facilitating the infiltration of immune effector cells and enhancing drug delivery, which collectively translate into improved tumour suppression, even in previously resistant cases.”

Remarkably, KCL-HO-1i presents a patient-friendly mode of administration. Unlike many cancer therapeutics that necessitate frequent hospital visits and invasive delivery methods, this drug is formulated as an oral tablet. Patients can conveniently take KCL-HO-1i at home during periods between chemotherapy sessions, greatly easing treatment burdens and improving adherence without compromising therapeutic outcomes.

The preclinical data supporting KCL-HO-1i’s potential are compelling. Utilizing robust mouse models of breast cancer, funded by Cancer Research UK and the Medical Research Council, the researchers demonstrated that combining KCL-HO-1i with standard chemotherapies significantly enhanced tumour regression across diverse chemotherapy regimens. These findings strongly suggest the drug’s utility may extend beyond breast cancer to a broad spectrum of solid tumours, magnifying its clinical impact.

Professor James Spicer, an authority in Experimental Cancer Medicine at King’s College London, remarks, “This drug represents a vital adjunct to current chemotherapy protocols. Our research unmasked one of the tumour’s stealth mechanisms and offered a tangible strategy to overcome it. We are eager to advance KCL-HO-1i into clinical trials to validate its safety and efficacy in patients, potentially transforming cancer care paradigms.”

Supporting this translational endeavor, Professor Miraz Rahman, Professor of Medicinal Chemistry, highlights the interdisciplinary collaboration underpinning this success. “Bridging immunology, chemistry, and clinical oncology enabled us to swiftly move from molecular target identification to drug development. Should clinical trials confirm preclinical promise, KCL-HO-1i could become an indispensable co-therapy, augmenting the effectiveness of existing cancer treatments and potentially reducing reliance on more aggressive therapeutic approaches,” he explains.

Experts beyond King’s College London echo excitement about this novel strategy. Tanya Hollands, Research Information Manager at Cancer Research UK, underscores the importance of optimizing existing treatments through rational combinations. “By pairing new agents like KCL-HO-1i with established chemotherapies, we may accelerate delivery of improved care, leveraging previous clinical experience while mitigating risk. This drug exemplifies the potential of precision medicine to refine and enhance conventional cancer therapy.”

Critical to the drug’s mechanism is reprogramming the tumour microenvironment from an immunosuppressive state to one conducive to immune activation and drug penetration. This reprogramming involves not only inhibiting HO-1 but also diminishing the production of immunosuppressive metabolites and signaling molecules. Subsequent immune infiltration and enhanced chemotherapy-induced cytotoxicity create a synergistic effect, profoundly influencing tumour control.

Looking ahead, the King’s College team anticipates that with appropriate funding, human clinical trials for KCL-HO-1i could commence within the next two years. These trials will probe not only safety and tolerability but also the drug’s capacity to overcome chemoresistance in diverse patient cohorts. Success in these studies would mark a pivotal advancement, becoming a new weapon in the oncologist’s arsenal against refractory cancers.

This discovery exemplifies the power of multidisciplinary research and innovative thinking in oncology. By targeting the cellular interplay within the tumour microenvironment rather than focusing solely on cancer cells, KCL-HO-1i represents a paradigm shift in therapeutic development. As the oncology community awaits clinical validation, this approach heralds a promising new chapter in the fight against resilient cancers, offering hope for improved survival and quality of life for patients worldwide.

Subject of Research: Development of a novel inhibitor targeting heme oxygenase-1 (HO-1) in tumour-associated macrophages to enhance chemotherapy efficacy.

Article Title: Not provided.

News Publication Date: Not provided.

Web References:

• Aethox Therapeutics

References:

• Full scientific article published in Science Translational Medicine (specific link not provided).

Image Credits:
Credit: King’s College London

Keywords:
Cancer, Cancer immunotherapy, Chemotherapy, Cancer medication, Medical treatments, Clinical medicine, Health and medicine, Life sciences, Pharmacology, Pharmaceuticals

This critical failure of ICIs to deliver durable remissions for all lung cancer patients has propelled intense research efforts over the past few years to develop novel therapeutic strategies. Researchers are focusing not only on overcoming innate resistance mechanisms but also on combating the sophisticated tumor evasion tactics that emerge after treatment initiation. The goal is to engineer next-generation immunotherapies that can awaken the immune system in more potent and multifaceted ways, broadening the spectrum of patients who can benefit and prolonging disease control. The recent regulatory approvals of two innovative immunotherapeutic agents in 2024 have marked pivotal milestones in this journey. The first, ivonescimab—a bispecific antibody targeting both PD-1 and vascular endothelial growth factor (VEGF)—received approval in China for non-small-cell lung cancer (NSCLC), showcasing a novel approach that merges immune checkpoint blockade with anti-angiogenic therapy. The second, tarlatamab, a bispecific T cell engager targeting delta-like ligand 3 (DLL3) and CD3, was authorized in the United States for small cell lung cancer (SCLC), representing a breakthrough in harnessing T cells to directly engage neuroendocrine tumor cells.

These successes represent compelling proof-of-concept that innovative immunotherapeutic modalities can effectively surmount the barriers posed by checkpoint inhibitor resistance. They have sparked renewed enthusiasm and accelerated a wave of clinical trials exploring a diverse array of novel agents with unique targets and mechanisms of action. Scientists and clinicians are investigating new immune checkpoint modulators that extend beyond the PD-1/CTLA-4 axis, immune cell engagers that redirect cytotoxic lymphocytes with precision, adoptive cell therapies that engineer patient-derived immune cells, and therapeutic cancer vaccines that stimulate tumor-specific immune responses. Each of these approaches attempts to disrupt the complex immunosuppressive tumor microenvironment and restore effective antitumor immunity.

The scientific rationale behind these next-generation immunotherapies reflects an evolving understanding of tumor-immune interactions. It is becoming clear that the immunosuppressive networks within lung tumors involve multiple checkpoints, cellular components, and molecular pathways that contribute to immune escape. Agents targeting novel co-inhibitory receptors such as LAG-3, TIGIT, and TIM-3 are being developed to reinvigorate exhausted T cells that no longer respond to conventional ICIs. Simultaneously, bispecific antibodies and T cell engagers are designed to bring immune effector cells into close contact with tumor cells, thereby bypassing some forms of resistance caused by lack of T cell infiltration or antigen presentation deficiencies.

Adoptive cell therapy has also gained traction as a promising avenue, with engineered chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-modified T cells tailored to recognize lung cancer-specific antigens. These cellular therapies seek to circumvent tumor evasion by directly supplying the immune system with cytotoxic lymphocytes that have enhanced specificity and potency. Unlike hematological malignancies where CAR T cell therapies have flourished, solid tumors such as lung cancer impose unique challenges—including antigen heterogeneity, immunosuppressive stroma, and physical barriers—that scientists are actively trying to overcome through innovations in CAR design and combination therapies.

Therapeutic cancer vaccines, too, are experiencing a renaissance. While earlier generations of vaccines produced disappointing results, advances in neoantigen identification, vaccine delivery platforms, and combination strategies with ICIs are reinvigorating this field. The objective is to prime the patient’s immune system against tumor-specific antigens, enhancing the breadth and durability of antitumor responses.

Despite the promise of these diverse immunotherapeutic strategies, numerous scientific and clinical hurdles remain. A fundamental challenge lies in the heterogeneity of lung cancers; both NSCLC and SCLC exhibit distinct biological behaviors and tumor microenvironments that influence immune responses. Understanding these nuances is vital for selecting appropriate immunotherapy platforms and designing combination regimens. Moreover, biomarker discovery and validation are crucial for predicting which patients are likely to benefit, thus avoiding unnecessary toxicity and optimizing treatment efficacy.

Safety concerns are equally significant. Novel immunotherapies can unleash intense inflammatory responses, sometimes leading to severe immune-related adverse events. The risk-benefit balance requires careful monitoring and the development of management protocols to mitigate toxicities. Additionally, regulatory frameworks and manufacturing complexities, particularly for cellular therapies, pose logistic and economic challenges that must be addressed to ensure broad patient access.

Multimodal approaches are increasingly favored in addressing these challenges. Combining next-generation immunotherapies with existing treatments—such as chemotherapy, radiation, antiangiogenics, or other immunomodulatory agents—may produce synergistic effects that overwhelm tumor defenses. Clinical trials testing countless combinations are underway, incorporating advanced biomarker analyses and adaptive trial designs to streamline development.

The clinical development pipeline for next-generation lung cancer immunotherapies is vibrant. Numerous agents have reached late-phase trials, indicating their translational potential. For example, some bispecific antibodies beyond ivonescimab are being evaluated for their ability to simultaneously block immune checkpoints and target other tumor-promoting pathways. Engineered T cell therapies are entering sophisticated trials where the tumor microenvironment is being modulated to enhance cellular infiltration and persistence. Cancer vaccines are being combined with ICIs in hopes of converting immunologically “cold” tumors into “hot” tumors responsive to immunotherapy.

These endeavors reflect the complexity and ambition of the current clinical research landscape. Each innovative agent and combination represents an incremental step toward overcoming resistance, enhancing response rates, and ultimately transforming lung cancer treatment paradigms. The integration of cutting-edge technologies such as single-cell sequencing, multiplex immunohistochemistry, and artificial intelligence-driven biomarker analysis accelerates the pace of discovery and refines therapeutic strategies.

Looking forward, the future of lung cancer immunotherapy lies in personalized, precision approaches that harness comprehensive molecular and immunological tumor profiles. By dissecting the mechanisms underlying both intrinsic and acquired resistance, future therapies can be rationally designed to preempt or counteract these evasive tactics. Equally important is the development of real-time monitoring tools to dynamically assess treatment response and alter therapeutic strategies promptly.

In sum, the emergence of next-generation immunotherapies heralds a promising era in lung cancer treatment. Regulatory approvals such as those of ivonescimab and tarlatamab underscore the clinical viability and therapeutic potential of innovative immune-targeting strategies. As research expands our understanding of tumor immunobiology and refines novel agents, immunotherapy is poised to extend its benefits to a broader patient population, improve survival outcomes, and reduce the mortality burden of both non-small-cell and small cell lung cancers. The excitement within the oncology community is palpable, driven by the prospect that these cutting-edge therapies will finally overcome the stubborn challenge of ICI resistance and change the course of this deadly disease.

Subject of Research: Next-generation immunotherapies and resistance mechanisms in non-small-cell and small cell lung cancers.

Article Title: The next generation of immunotherapies for lung cancers.

Article References:

Zhao, S., Zhao, H., Yang, W. et al. The next generation of immunotherapies for lung cancers.
Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01035-9

Image Credits: AI Generated